Clinical Trial Results - Eli Lilly's experimental pill Orphon showed an 11% weight loss in patients [1] - Novo Nordisk's weight loss shot Wegovy led to a 15% body weight reduction in trials [2] - Eli Lilly's shot Zepbound demonstrated even better weight loss results than Wegovy [2] Market Expectations and Reactions - Wall Street anticipated Orphon to perform better, aligning with injectable drugs [1] - Investors showed a negative reaction to Orphon's results, indicated by a share price decrease [1] - Pills are considered crucial for expanding market reach, in a market projected to reach $95 billion by 2030 [3] Development and Approval - Eli Lilly plans to submit Orphon's findings for approval by the end of the year [4] - The daily weight loss pill could potentially be available in pharmacies as early as 2026, pending approval [4] - Pharmaceutical companies like Pfizer and AstraZeneca have previously encountered setbacks in developing weight loss pills [3]

Clinical Trial Results & Market Reaction - Eli Lilly's experimental pill Orphon showed an 11% weight loss in patients during a late-stage clinical study [1] - Despite the positive results, Eli Lilly's shares fell, as Wall Street anticipated better performance in line with injectable weight loss drugs [1] - Novo Nordisk's Wegovy showed up to 15% weight loss in trials [2] - Eli Lilly's Zepbound had even better weight loss results than Wegovy [2] Market Potential & Challenges - Analysts forecast the weight loss market to grow to $95 billion by 2030 [3] - Pills are considered key to reaching a broader patient base in the weight loss market [3] - Developing effective weight loss pills has been challenging, with Pfizer and AstraZeneca facing setbacks [3] Future Plans - Eli Lilly plans to submit Orphon's findings for approval by the end of the year [4] - If approved, Orphon could be available in pharmacies as early as 2026 [4]